FDA Grants Dacomitinib Priority Review for Frontline EGFR+ NSCLC
April 4, 2018 - The FDA has granted a priority review designation to dacomitinib for the frontline treatment of patients with EGFR-positive locally advanced or metastatic non–small cell lung cancer (NSCLC), according to Pfizer, the manufacturer of the pan-human EGFR ...Leggi tutto
